€3.04
4.97% yesterday
L&S, Jul 04, 10:54 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$3.12
-1.22 28.11% 1M
-1.05 25.18% 6M
-1.09 25.89% YTD
-7.65 71.03% 1Y
-61.64 95.18% 3Y
-52.78 94.42% 5Y
-52.78 94.42% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
-0.22 6.59%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $699.83m
Enterprise Value $419.56m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.57
P/S ratio (TTM) P/S ratio 10.96
P/B ratio (TTM) P/B ratio 1.45
Revenue growth (TTM) Revenue growth 22.14%
Revenue (TTM) Revenue $63.88m
EBIT (operating result TTM) EBIT $-322.16m
Free Cash Flow (TTM) Free Cash Flow $-333.83m
Cash position $324.16m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 15.24
EV/Sales forward 9.13
Short interest 14.69%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a CureVac N.V. forecast:

4x Buy
50%
3x Hold
38%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from CureVac N.V.

Assets
Mar '24
408 408
Cash 324 324
Claims 32 32
Inventories 28 28
Other current assets Other current assets Current assets 23 23
338 338
Property, plant and equipment 301 301
Financial assets - -
Intangible Assets 34 34
Other fixed assets Other assets Fixed assets 2.37 2.37
Total Assets 746 746
Liabilities
Mar '24
Equity 483 483
263 263
Current liabilities 181 181
Non-current liabilities 82 82
Total Capital 746 746

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Negative
InvestorPlace
one day ago
CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce.
Positive
Barrons
one day ago
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
Positive
InvestorPlace
one day ago
CureVac (NASDAQ: CVAC ) stock is on the rise Wednesday after the company announced a restructured licensing agreement with GSK (NYSE: GSK ). This new agreement has GSK taking over the development and manufacturing of certain vaccines made by CureVac.
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 1,172
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today